reports
- Jonathan Moreland
Exelon Crews and Equipment Deployed to Florida for Power Restoration E...
CHICAGO--(BUSINESS WIRE)-- In a unified effort to support communities impacted by Hurricane Milton, Exelon has deployed more than 600 field and support personnel to aid in power restoration after the storm’s landfall. Recognizing the urgency and potential devastation of the storm, Exelon’s utility companies swiftly mobilized resources to ensure local Florida utility companies have the support needed to address power outages safely and promptly. This follows Exelon’s recent dispatch of hundreds of crews to assist in the aftermath of Hurricane Helene. This press release features multimedia. View...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
GUESS?, Inc. Partners with SuperCircle for New E-Commerce Recycling Pr...
LOS ANGELES--(BUSINESS WIRE)-- GUESS launches GUESS Again, a customer recycling program in partnership with SuperCircle, the textile recycling platform powering consumer trade-in for leading brands and retailers investing in a circular future. This press release features multimedia. View the full release here: (Photo: Business Wire) This initiative complements the brand’s in-store customer recycling program in partnership with Homeboy Threads, a certified social enterprise offering reuse and recycling services for apparel and textiles. Customers can bring in five or more articles of clothing o...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatm...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors. HYMPAVZI is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for the treatment of...
Climb Bio Announces Abstract Selected for Presentation at the American...
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024. Poster Presentation A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous NephropathyPresenter: Frank Cortazar, M.D., Director, New York Nephrology Vasculitis and Glo...
Fuller, Smith & Turner PLC: Transaction in own shares
Fuller, Smith & Turner PLC (FSTA) Fuller, Smith & Turner PLC: Transaction in own shares 11-Oct-2024 / 17:15 GMT/BST Fuller, Smith & Turner P.L.C. (“the Company” or “Fuller’s”) Transaction in own shares The Company announces that it has purchased the following number of its ‘A' ordinary shares of 40p each on the London Stock Exchange through Numis Securities Limited as part of its share buyback programme announced on 23 August 2024 (the “Programme”). Date of Purchase 11/10/2024 Number of ‘A’ ordinary shares of 40p each 11,324 ...
Funding Circle Plc: POS-Transaction in Own Shares
Funding Circle Plc (FCH) Funding Circle Plc: POS-Transaction in Own Shares 11-Oct-2024 / 17:16 GMT/BST LEI: 2138003EK6UAINBBUS19 11 October 2024 Funding Circle Holdings plcTransaction in own shares Funding Circle Holdings plc (the "Company") announces that it has purchased for cancellation the following number of its ordinary shares of £0.001 each on the London Stock Exchange from Numis Securities Limited (“Deutsche Numis”) as part of its buy-back announced on 7 March 2024: Date of purchase: 11 October 2024 Number of ordinary shares purchased: ...
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Expanding its pipeline to include non-oncology products, an opportunistic approach aimed at maximizing ROI from its ExacTcell™ technology. WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers,...
Festi hf.: Changes in Festi‘s Executive Management
Festi hf.: Changes in Festi‘s Executive Management Karen Ósk Gylfadóttir has been appointed Managing Director of Lyfja hf. as of today and will join the Executive Management team of Festi. Karen Ósk holds a business degree from the University of Iceland. Over the past three years, she has served as Director of Product and Marketing and Digital Development at Lyfja. Before that, she was the Marketing Director at Nova hf. Karen Ósk will succeed Hildur Þórisdóttir, who has served as acting CEO of Lyfja, in addition to her previous role as Managing Director of Lyfja‘s Human Resource De...
Festi hf.: Breyting á framkvæmdastjórn
Festi hf.: Breyting á framkvæmdastjórn Karen Ósk Gylfadóttir hefur verið ráðin framkvæmdastjóri Lyfju hf. frá og með deginum í dag en samhliða því tekur hún sæti í framkvæmdastjórn Festi. Karen Ósk er viðskiptafræðingur frá Háskóla Íslands. Hún hefur síðastliðin þrjú ár gegnt starfi framkvæmdastjóra vöru- og markaðssviðs og stafrænnar þróunar hjá Lyfju en þar á undan starfaði hún sem markaðsstjóri Nova hf. Karen Ósk tekur við af Hildi Þórisdóttur, sem hefur verið starfandi framkvæmdastjóri Lyfju, samhliða fyrra starfi sínu sem framkvæmdastjóri mannauðssviðs, frá ágúst 2023. Hildu...
JACQUET METALS SA : Déclaration au titre de l'article 223-16 du Règlem...
SAINT-PRIEST, France--(BUSINESS WIRE)-- Regulatory News: Jacquet Metals SA (Paris:JCQ): Date Nombre d'actions composant le capital Nombre de droits de vote théoriques 30 septembre 2024 22 016 467 31 785 949 Le nombre total des droits de vote exerçables attachés à ces 22 016 467 actions s’élève à 30 720 471 droits de vote en tenant compte des 1 065 478 actions autodétenues par JACQUET METALS SA et privées de droits de vote en vertu des articles L.225-111 et L.225-210 du Code de commerce. Consultez la version source sur businesswire.com :
Organisation d’une visioconférence destinée aux actionnaires et invest...
BRUSSELS--(BUSINESS WIRE)-- Regulatory News: Llama Group SA (Paris: ALLAM) (Brussels: ALLAM), société pionnière et leader dans l’industrie de la musique digitale annonce l’organisation d’une visioconférence à destination des actionnaires et investisseurs individuels le : JEUDI 17 OCTOBRE A 18H30 Cette visioconférence sera l’occasion de revenir sur les résultats semestriels, les dernières actualités et de permettre aux actionnaires individuels actuels ou futurs d’échanger avec Alexandre Saboundjian, Président Directeur Général et Olivier Van Gulck, Directeur Administratif et Financier. Pour...
GROUPE PARTOUCHE : Pérennisation par Patrick Partouche du contrôle de ...
GROUPE PARTOUCHE : Pérennisation par Patrick Partouche du contrôle de la Financière Partouche, actionnaire majoritaire de Groupe Partouche Pérennisation par Patrick Partouche du contrôle de la Financière Partouche, actionnaire majoritaire de Groupe Partouche Paris, le 11 octobre 2024, à 18h Groupe Partouche a été informée par son actionnaire majoritaire à 66,83 %, la société Financière Partouche détenue par la famille Partouche, que cette dernière a approuvé l’octroi de droits de vote multiples à Monsieur Patrick Partouche, conférant de ce fait à ce dernier plus de la majorité des droit...
- Pierre FerraguÊ
Moody's Ratings upgrades the ratings on EUR 78.8m CLO notes of Harvest...
Moody's Ratings (Moody's) has upgraded the ratings on the following notes issued by Harvest CLO XV DAC: ....EUR 31,500,000 Class C-R Senior Secured Deferrable Floating Rate Notes due 2030, Upgraded to Aaa (sf); previously on Feb 14, 2024 Upgraded to Aa3 (sf) ....EUR 24,200,000 Class D-R Senior Se...
Issue of Equity
M&G Credit Income Investment Trust plc (MGCI) Issue of Equity 11-Oct-2024 / 16:47 GMT/BST 11 October 2024 LEI: 549300E9W63X1E5A3N24 M&G Credit Income Investment Trust plc Issue of Equity M&G Credit Income Investment Trust plc (the “Company”) announces that, on 11 October 2024, it sold from treasury at a premium to the last published net asset value 50,000 ordinary shares of one penny each (the “Ordinary Shares”) for cash at a price of 97.40 pence per Ordinary Share. The new Ordinary Shares were credited as fully paid and rank pari passu with the existing Ordinary Sha...
Lumibird : nombre d'actions au 30 septembre 2024
Lumibird : nombre d'actions au 30 septembre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par les articles L.233-8 II du Code de commerce et 223-16 du Règlement général de l’Autorité des Marchés Financiers DateNombre d’actions composantle capitalNombre réel de droits devote1Nombre théorique droits devote2 30 septembre 2024 22 466 882 33 677 654 34 140 357 Déduction faite des actions auto-détenuesY compris actions auto-détenues, en application de l’article 223-11, alinéa 2, du Règlement général de l’Autorité des Marchés Financiers LUMIBIRD - 2 ...
Acticor Biotech repositionne glenzocimab dans le traitement de l'infar...
PARIS--(BUSINESS WIRE)-- Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), société de biopharmaceutique au stade clinique spécialisée dans le développement de médicaments innovants pour le traitement des urgences cardiovasculaires et notamment les maladies thrombotiques aigues, fait aujourd’hui le point sur ses développements cliniques, évaluant glenzocimab dans le traitement de l’infarctus du myocarde. Gilles AVENARD, Directeur Général et fondateur d’Acticor Biotech, commente : « L'infarctus du myocarde constitue une cause majeure de décès dans le monde, représentant 7 à 9 millions d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.